glp-1 drugs pharmaceutical companies 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo The Biggest Winner of GLP-1

The outcome was thyroid cancer (international classification of diseases, 10th revision, code C73) identified from nationwide cancer registers

For those using Semaglutide GLP-1 for diabetes management , improvements in glucose control may appear within days, while weight management benefits generally become more noticeable over several weeks

As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)

Proper reconstitution is essential

Some patients take GLP-1s for a shorter time to jumpstart their weight loss, while others may benefit from extending their treatments to help improve health conditions or for continued weight management support